Our evidence supports the prioritization of future clinical trials of SGLT2 inhibitors in diabetic men at high risk of prostate cancer, which may have the potential to influence clinical guidelines/standards for diabetes. The gene discussed is SLC5A2; the disease is prostate cancer.